Edwards Lifesciences (EW) is a leading company in the artificial heart valve market, and it’s the largest player in the TAVR (transcatheter aortic valve replacement) market.
For more information on the company’s long-term growth strategy, read Edwards Lifesciences Sees Growth on Long-Term Growth Strategy.
The company was trading at $114.6 on May 30, 2017, with a 50-day moving average of $107.1 and a 200-day moving average of $95.9. On May 30, 2017, EW stock was trading ~41% above its 52-week low of $81.1 as of December 1, 2016, and ~-6% below its 52-week high of $121.7 as of October 10, 2016.
EW’s stock price has risen ~17% since it released its 1Q17 results on April 25, 2017. In 1Q17, EW posted higher-than-expected earnings and exceeded analysts’ estimates. The company provided positive guidance for the full year. The company’s stock price rose ~12% the day following the announcement.
Comparisons with industry and market performances
Edwards Lifesciences stock has returned ~14.6% in the past 12 months, underperforming the SPDR S&P 500 Index (SPY), which has returned ~15% during the same period.
EW’s stock performance can also be compared to the US medical device sector’s performance as represented by the iShares US Medical Devices ETF (IHI). Edwards Lifesciences has returned ~22% on a YTD (year-to-date) basis, compared to the 7.8% and 21% YTD returns generated by SPY and IHI, respectively.